Adheris Health Limited · ASX:AHE
Adheris Health — Investor Presentation (September 2019)
29 slides from Adheris Health's investor presentation, Sep 5, 2019
Slide 1: Globalising Medication Management
making medication manageable Globalising Medication Management 2019 1
Slide 2: Important Notice
making Important Notice medication manageable This Presentation dated 5 September 2019 and has been prepared by MedAdvisor International Pty Ltd ACN 161 366 589 (MedAdvisor or the Company) for information purposes only. This Presentation is not an offer or invitation to acquire securities in MedAdvi
Slide 3: Our Core Purpose
making Our Core Purpose medication manageable Me d Ad vis o r is t a c klin g t h e glo b a l is s u e o f medication non - adherence a n d p o o r h e a lt h lit e ra c y t o d rive im p ro ve d h e a lt h o u t c o m e s fo r p a t ie n t s b y m a k in g m e d ic a t io n m a n a ge a b le . 3
Slide 4: Investment Proposition
making Investment Proposition medication manageable MedAdvisor has launched a global platform through expansion into the UK, US and Asia, building on an established high margin, recurring revenue Australian SaaS business. • >1.2m connected Australian patients (~10% of potential market) with >55% pha
Slide 5: The Global Opportunity
The Global Opportunity MedAdvisor’s role in Making Medication Manageable www.medadvisor.com.au 5
Slide 6: Poor patient adherence to medication is a global issue
making Poor patient adherence to medication is a global issue medication manageable Improving patient adherence has multiple beneficiaries Pharmacists & Doctors Patients Pharma Companies & Payors* *Healthcare payors vary in each jurisdiction and include Governments and Insurers The WHO estimates adh
Slide 7: Changing global landscape impacting Pharmacy
making Changing global landscape impacting Pharmacy medication manageable Pressure on Pharmacy’s traditional model Funding reducing for Must diversify revenue dispense fees; needing to streams – offer more shift to services revenue medicines & health services Pharmacists Competition from Offer patie
Slide 8: The Solution: MedAdvisor Global Platform
Pharmacists & Doctors Patients Pharma Companies & Payors The Solution MedAdvisor Global Platform MedAdvisor Global Platform MedAdvisor mobile app ratings: 4.6 4.5 4.5 www.medadvisor.com.au 3,214 Total 940 All Vers ions 15,543 Likes 8
Slide 9: MedAdvisor Global Platform
making MedAdvisor Global Platform medication manageable Driving improved adherence & health literacy Pharmacy Patients Pharma Companies & Payors PlusOne MedAdvisor App & Messaging Health Programs A SaaS platform for pharmacies that A free mobile app for patients that A platform for pharma companies
Slide 10: How we do it
making How we do it medication manageable Workflow Efficiencies and Simple Convenience Pharmacists & Doctors Patients Pharma Companies & Payors Prescriber/ Access to hard to Dispense Data reach audiences Integrations with Medication made manageable Efficient distribution prescribing and/or Accessibl
Slide 11: The network effect
making The network effect medication manageable Benefits of adherence accrue to all stakeholders Pharmacists & Doctors Pharma Companies & Payors • Make patients more loyal • Increase adherence +20% • Improve Adherence to to drive more revenue improve patient outcomes • Improve workflow with 57% and
Slide 12: MedAdvisor Drives Revenue & Saves Pharmacists Time
making MedAdvisor Drives Revenue & Saves Pharmacists Time medication manageable >8x ROI, Saves Time, Improves Loyalty, Streamlines Delivery of Patient Services Sample In-Pharmacy MedAdvisor Dashboard: PlusOne – Health Services Hub • 57% of orders coming in out of hours = workflow efficiency • Saves
Slide 13: Pharmaceutical Company Case Study
making Pharmaceutical Company Case Study medication manageable Health Program - Digital Adherence Issue Poor adherence to Asthma Medication is a well established issue. Reasons include: • inadequate training in inhalation technique; • anxiety regarding side effects; • inconvenience of the treatment;
Slide 14: MedAdvisor's impact on patient adherence is material
making MedAdvisor’s impact on patient adherence is material medication manageable Up to 10x ROI for Pharma Companies, +1 - 2 scripts/year for pharmacy ROIs for pharmaceutical companies based on adherence Additional scripts per patient per year for pharmacy Better Health uplifts Outcomes Up to 10x RO
Slide 15: Australian Domestic Business
Australian Domestic Business A strong, growing core www.medadvisor.com.au 15
Slide 16: Who we work with
making Who we work with medication manageable Health Care Providers Patients Pharma Companies & Payors Pharmacy Groups Pharmaceutical Companies 16
Slide 17: Building a growing annuity stream from multiple revenue sources
making Building a growing annuity stream from medication manageable multiple revenue sources Patients Pharmacists & Doctors Pharma Companies & Payors Community Pharmacy Pharmaceutical Companies PlusOne Pharmacy Software MedAdvisor App Health Programs • SaaS + patient messaging fees • Patient -initia
Slide 18: Significant potential in the Australian market connecting more patients & programs
making Significant potential in the Australian market medication manageable connecting more patients & programs 5,700 Pharmacies 12m Chronic Patients A$660m increase in healthcare costs due to non-adherence 5,700 12m $120m Australia is just 2% of 3,300 7m the global Total Available 55% share Patient
Slide 19: International Expansion
International Expansion 3 Key Markets: US, Asia and the UK www.medadvisor.com.au 19
Slide 20: Global partnerships leading to scaled revenue opportunities in FY20
making Global partnerships leading to scaled revenue medication manageable opportunities in FY20 Firs t cus tom er s igned in the UK. Leading pharm acy chain in the UK with 270 pharm acies and ~ 1m cus tom ers Agreement with Adheris J V form ed May ’19 for a 50/ 50 J V Health delivers the to deliver
Slide 21: US Market Entry to Lead with Pharma Company Health Programs via Adheris Partnership
making US Market Entry to Lead with Pharma Company medication manageable Health Programs via Adheris Partnership US market is highly attractive to MedAdvisor due to: 60,000 • Largest pharmaceutical market in the world and dem ons trated willingnes s to inves t in pos itive ROI Pharm acies patient co
Slide 22: UK Market Entry to Lead with Day Lewis Pharmacy Group in early 2020
making UK Market Entry to Lead with Day Lewis Pharmacy medication manageable Group in early 2020 UK market is attractive to MedAdvisor due to: 14,000 • Combination of corporatized ownership groups & independents Pharm acies • Cloud based script information through the NHS technology backbone reduces
Slide 23: SE Asian Market Entry being led via JV with Zuellig Pharma
making SE Asian Market Entry being led via medication manageable JV with Zuellig Pharma South-East Asia is attractive to MedAdvisor due to: 90,000 Pharm acies • Rapid digital health take-up across the region that needs to digitise • Multi -faceted JV partner, Zuellig Pharma, brings 100 year history,
Slide 24: Global Competition Overview
making Glo b a l Co m p e t it io n * Ove rvie w medication manageable Pharmacy Ordering Dispense Digital Adherence App Condition Competitor Dose reminders Professional GP Connectivity Medication Integration Programs Specific functionality Services MedAdvisor Guildlink Medisafe (Israel/Global) mScri
Slide 25: Financial Performance
Financial Performance FY19 Results www.medadvisor.com.au 25
Slide 26: FY19 Results show significant progress in driving revenue and core EBITDA
FY19 Re s u lt s s h o w s ign ific a n t p ro gre s s in making medication manageable d rivin g re ve n u e a n d c o re EBITDA Operating Revenue Revenue per Pharmacy (SaaS & User Based) 3YR CAGR– 37% Comments 25% 12% Total Operating Revenue for FY19 of 8.2 55% $8.2m , 25% growth. 56% Total Reven
Slide 27: Opex profile reflects strong growing core business
Op e x p ro file re fle c t s s t ro n g gro w in g c o re b u s in e s s , making medication manageable w it h in ve s t m e n t in d e ve lo p in g c a p a b ilit y d o m e s t ic a lly a n d in t e rn a t io n a lly Gross margin to expenses Comments (Growth and Fixed Opex) 16.3 Profitable core
Slide 28: MedAdvisor Has Attracted a Strong Executive Team
making Me d Ad vis o r Ha s At t ra c t e d a St ro n g Exe c u t ive medication manageable Te a m Robert Read Victor Kovalev Simon Glover Simon Chamberlain CEO & MD CTO & Head of Product CFO GM Strategy Robert has been CEO of MedAdvis or s ince J uly 2015 taking Victor is a s enior product engineer
Slide 29: Corporate Overview
making Co rp o ra t e Ove rvie w medication manageable MedAdvisor Ltd (ASX:MDR) Top Shareholders Shares on Issue (as at 9 July 2019) 1,371m Options ($0.035, $0.04 & $0.08 s trike prices ) 21m Board & Managem ent ~ 29% Em ployee Options (including Read Perform ance Rights ) 47m Regal Funds Managem en
Adheris Health — Investor Presentation (September 2019) on 6ix